Results 161 to 170 of about 94,421 (295)

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: advancing care with caution. [PDF]

Ann Med Surg (Lond)
Rehman Z, Ahsaan F, Latif B, Anjum AF, Yokolo H.   +4 more
europepmc   +1 more source

Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs [PDF]

, 2017
Bracke, Marc, Roman, Bart, Stevens, Christian, Verhasselt, Sigrid   +3 more
core   +2 more sources

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Exercise‐specific plasma proteomic signatures in racehorses: Candidates for training adaptation and peak load monitoring

Equine Veterinary Journal, EarlyView.
Abstract Background Racehorses undergo profound physiological changes with training and competition, but current biomarkers inadequately capture the complex molecular dynamics of exercise. This study aimed to identify novel plasma biomarkers of training adaptation and peak load using high‐throughput proteomics.
Jowita Grzędzicka, Bianka Świderska, Ewa Sitkiewicz, Izabela Dąbrowska, Olga Witkowska‐Piłaszewicz   +4 more
wiley   +1 more source

Effects of myosin inhibitors on the X-ray diffraction patterns of relaxed and calcium-activated rabbit skeletal muscle fibers. [PDF]

Biophys Physicobiol, 2018
Iwamoto H.
europepmc   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Actin and Rho GTPases in herpesvirus biology [PDF]

, 2007
ENQUIST, LW, Favoreel, Herman, FEIERBACH, B   +2 more
core   +1 more source